Institute for Infectious Diseases and Infection Control, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany.
Institute for Infectious Diseases and Infection Control, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany; Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.
Clin Microbiol Infect. 2022 Jul;28(7):1026.e7-1026.e11. doi: 10.1016/j.cmi.2022.03.025. Epub 2022 Mar 28.
Classification of Staphylococcus aureus bacteraemia (SAB) as 'complicated' or 'uncomplicated' and management of both is based on low-quality evidence. The aim of the study was to determine the degree of agreement among infectious diseases physician experts in the management of patients with SAB.
A stepwise RAND-modified Delphi procedure with two questionnaire rounds was performed. Four aspects of management in 22 clinical scenarios were addressed: (a) classification of SAB episodes; (b) value of combination therapy; and (c) timing of and (d) preferred antibiotics for oral stepdown therapy.
Out of 90 approached experts, 33 (36.7%) from 14 different countries and 5 continents consented to participate. The experts considered any of the discussed implanted foreign material (with no evidence of infection), except for coronary artery stents, as relevant to the classification of a complicated SAB episode. Concerning antibiotic combination therapy, the experts strongly agreed that combination therapy with rifampicin is only relevant in patients with prosthetic valve endocarditis and prosthetic joint infection. The experts considered an oral stepdown therapy in patients with an uncomplicated SAB within 14 days and only thereafter in patients with a complicated SAB episode, but never in patients with prosthetic valve endocarditis. No single antibiotic of choice for oral stepdown therapy could be identified, neither for infections with methicillin-resistant S. aureus nor methicillin-susceptible S. aureus.
The Delphi survey can help physicians in their day-to-day decision-making process, and it reveals open questions that must be investigated by further studies.
金黄色葡萄球菌菌血症(SAB)的分类为“复杂”或“不复杂”,两者的管理均基于低质量的证据。本研究旨在确定感染病学专家在处理 SAB 患者时的管理意见的一致性程度。
采用两步 RAND 改良 Delphi 程序进行两轮问卷调查。针对 22 种临床情况下的 4 个管理方面进行了讨论:(a)SAB 发作的分类;(b)联合治疗的价值;(c)口服降阶梯治疗的时机;(d)首选抗生素。
在 90 位受邀专家中,来自 14 个不同国家和 5 个大洲的 33 位(36.7%)同意参与。专家认为,除了冠状动脉支架外,任何讨论的植入性异物(无感染证据)都与复杂 SAB 发作的分类相关。关于抗生素联合治疗,专家强烈认为,只有在患有人工瓣膜心内膜炎和人工关节感染的患者中,联合使用利福平才具有相关性。专家认为,对于无并发症的 SAB 患者,应在 14 天内进行口服降阶梯治疗,仅在复杂 SAB 发作的患者中进行,而绝不在患有人工瓣膜心内膜炎的患者中进行。对于耐甲氧西林金黄色葡萄球菌或甲氧西林敏感金黄色葡萄球菌感染,都无法确定单一的首选口服降阶梯治疗抗生素。
Delphi 调查可以帮助医生在日常决策过程中做出决策,并揭示出必须通过进一步研究来解决的悬而未决的问题。